Mounjaro vs Ozempic for Men with Diabetes and Obesity in 2026

Tirzepatide (Mounjaro) produces greater weight loss than semaglutide (Ozempic) in men managing both type 2 diabetes and obesity — and the gap is large enough to matter clinically. The tradeoff is that Ozempic carries a deeper cardiovascular outcomes record, which still matters when your patient has established heart disease.

Efficacy: Where the Numbers Actually Diverge

Mounjaro's edge comes from its dual mechanism. As a GIP/GLP-1 co-agonist, it recruits two incretin pathways simultaneously [4]. Ozempic hits only the GLP-1 receptor. That difference shows up in the trial data: SURMOUNT-1, published in NEJM, showed tirzepatide producing up to 20.9% mean weight loss at 72 weeks in adults with obesity. Semaglutide's STEP-1 trial, also in NEJM, landed at 14.9%. Even controlling for the dose difference, tirzepatide's weight-loss signal is consistently stronger [3].

For glycemic control, the picture is similar. Head-to-head trials comparing Mounjaro to Ozempic in type 2 diabetes show tirzepatide achieving greater A1c reductions across all tested doses [6]. Both drugs reduce fasting glucose in a glucose-dependent fashion, which keeps standalone hypoglycemia risk low — a real advantage for men already on complex medication regimens.

Men as a subgroup do tend to lose slightly less weight than women on GLP-1–based therapies in absolute percentage terms, though the effect remains clinically meaningful [5]. If maximum weight loss is the priority alongside diabetes control, Mounjaro is the stronger tool. You can compare vetted providers for both at Alpha Health Finder's advanced therapies hub.

Cardiovascular Evidence and Safety Signals

Ozempic holds a meaningful advantage in cardiovascular outcome data. The SELECT trial, published in NEJM in 2023, demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease — a landmark result that directly applies to the typical male patient with long-standing diabetes and coronary risk. Mounjaro's cardiovascular outcomes trial is ongoing; the data aren't in yet.

Both drugs carry FDA boxed warnings regarding theoretical thyroid C-cell tumor risk — flagged under the agency's labeling requirements for GLP-1 receptor agonists — and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 [8]. Gastrointestinal side effects (nausea, vomiting, constipation) are broadly similar between the two, though individual tolerance varies. Men who've struggled with Ozempic's GI profile don't necessarily get a free pass with Mounjaro. For a deeper look at how these drugs interact with thyroid risk, see what the tumor data actually shows.

If cardiovascular protection is the dominant clinical priority and the patient has documented heart disease, Ozempic's evidence base is currently stronger. If weight loss and glycemic control are leading the decision and cardiovascular outcomes data can wait, Mounjaro wins on efficacy. Marek Health manages both and offers structured protocols for men with metabolic comorbidities — see their profile at Marek Health on AHF.

It's also worth noting that GLP-1 therapy can affect testosterone levels indirectly through weight loss — men who are curious about hormonal downstream effects should read what GLP-1 does to hormone levels.

---

Frequently asked questions

Which drug produces more weight loss — Mounjaro or Ozempic?

Mounjaro (tirzepatide) produces greater average weight loss than Ozempic (semaglutide) based on current trial data. SURMOUNT-1 showed up to 20.9% weight reduction with tirzepatide versus approximately 14.9% in STEP-1 with semaglutide. For men with obesity and type 2 diabetes, the absolute difference typically translates to 10–20 additional pounds lost.

Does Ozempic have better heart-protection data than Mounjaro?

Yes, as of June 2026, Ozempic has stronger cardiovascular outcomes evidence. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in patients with obesity and established cardiovascular disease. Tirzepatide's equivalent outcomes trial has not yet reported results, making Ozempic the better-supported choice when cardiac risk reduction is the primary goal.

Can men with type 2 diabetes use compounded versions of these drugs?

Compounded semaglutide and compounded tirzepatide are available through 503A and 503B pharmacies, though FDA has signaled increasing scrutiny of these products as branded versions return to stable supply. Compounded versions are not FDA-approved and lack the clinical trial validation of Ozempic or Mounjaro. Men considering this route should work with a licensed prescriber who can monitor A1c, weight, and safety markers systematically.